DK2435825T3 - Fremgangsmåder til sygdomsbehandling - Google Patents

Fremgangsmåder til sygdomsbehandling Download PDF

Info

Publication number
DK2435825T3
DK2435825T3 DK10779928.0T DK10779928T DK2435825T3 DK 2435825 T3 DK2435825 T3 DK 2435825T3 DK 10779928 T DK10779928 T DK 10779928T DK 2435825 T3 DK2435825 T3 DK 2435825T3
Authority
DK
Denmark
Prior art keywords
measurements
disease
biomarker
cells
therapy
Prior art date
Application number
DK10779928.0T
Other languages
English (en)
Inventor
Martin Leonard Ashdown
Andrew Robinson
Original Assignee
Biotempus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotempus Ltd filed Critical Biotempus Ltd
Application granted granted Critical
Publication of DK2435825T3 publication Critical patent/DK2435825T3/da

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/413—Monitoring transplanted tissue or organ, e.g. for possible rejection reactions after a transplant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235—Details of waveform analysis
    • A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
    • A61B5/7267—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems involving training the classification device
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Claims (16)

1. Computerimplementeret fremgangsmåde til analyse af en biomarkør, der cirkulerer hos et individ med en sygdom, for at bestemme et foretrukket tidspunkt i fremtiden til at administrere en terapi til behandling af sygdommen, hvilken fremgangsmåde omfatter: a) estimering af en periodicitet for cirkuleringen af biomarkøren baseret på målinger af biomarkøren i prøver fra individet ved opnåelse af en best-fit kurve for målingerne i overensstemmelse med en model af biomarkørens cirkulering, hvor modellen er en periodisk regressionsteknik; og b) bestemmelse ud fra den estimerede periodicitet for cirkuleringen af et foretrukket tidspunkt i fremtiden til at administrere en terapi til at behandle sygdommen hos individet ved at projicere den opnåede best-fit kurve ind i fremtiden.
2. Fremgangsmåde ifølge krav 1, hvor best-fit kurven er tilpasset til en harmonisk model af biomarkørens cirkulering, og opnåelse af best-fit kurven endvidere omfatter tilpasning af den harmoniske model med målingerne talrige gange ved anvendelse af forskellige initiale betingelser for hver tilpasning.
3. Fremgangsmåde ifølge krav 2, hvilken fremgangsmåde endvidere omfatter generering af en konfidensmåling ved sammenligning af en lighed i et tilpasningsresultat, der er fremkommet ved hver tilpasning.
4. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor opnåelse af best-fit kurven endvidere omfatter at påtvinge mindst nogle parametre for den harmoniske model boksbegrænsninger for at styre optimeringen mod biologisk realistiske områder.
5. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor den harmoniske model har en tung hale for at tillade målingernes støjende natur.
6. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvilken fremgangsmåde endvidere omfatter bestemmelse af en variansstabiliserende transformation af målingerne forud for estimering af periodiciteten baseret på de transformerede målinger.
7. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor bestemmelse af det foretrukne tidspunkt til at administrere terapien omfatter sammenligning af målingerne af individet med en database med målinger af biomarkøren opnået fra andre individer.
8. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor målingerne er for to eller flere forskellige biomarkører, der cirkulerer hos individet, og bestemmelse af det foretrukne tidspunkt til at administrere terapien er baseret på de to eller flere sæt målinger.
9. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor biomarkøren er en markør for akut inflammationsfase.
10. Fremgangsmåde ifølge krav 1, hvilken fremgangsmåde endvidere omfatter: i) modtagelse af målinger af biomarkøren fra en måleanordning inden trin a) og ii) transmission af det foretrukne tidspunkt til måleanordningen efter trin b).
11. Fremgangsmåde ifølge krav 10, hvilken fremgangsmåde endvidere omfatter transmission af cirkuleringens estimerede periodicitet til måleanordningen.
12. Computerprogramprodukt omfattende computerprogramkodemidler til at bevirke, at en computer implementerer en fremgangsmåde ifølge et hvilket som helst af kravene 1 til 11.
13. Computersystem til analyse af en biomarkør, der cirkulerer hos et individ med sygdommen, for at bestemme et foretrukket tidspunkt i fremtiden til at administrere en terapi til behandling af sygdommen, hvilket system omfatter en beregningsanordning, der kan anvendes til at: a) estimere en periodicitet for cirkuleringen af biomarkøren hos individet baseret på målinger af biomarkøren i prøver fra individet ved opnåelse af en best-fit kurve til målingerne i overensstemmelse med en model af biomarkørens cirkulering, hvor modellen er en periodisk regressionsteknik; og b) bestemme ud fra cirkuleringens estimerede periodicitet et foretrukket tidspunkt i fremtiden til at administrere en terapi til behandling af sygdomme hos individet ved at projicere den opnåede best-fit kurve ind i fremtiden.
14. Computersystem ifølge krav 13, hvilket computersystem endvidere omfatter en måleanordning til analyse af en biomarkør, der cirkulerer hos et individ med en sygdom, hvilken måleanordning kan: i) sende målinger af biomarkøren til computersystemets beregningsanordning via et kommunikationsnetværk; og ii) modtage det foretrukne tidspunkt fra beregningsanordningen.
15. Computersystem ifølge krav 14, hvor måleanordningen endvidere kan anvendes til at modtage cirkuleringens estimerede periodicitet.
16. Computersystem ifølge krav 13 eller krav 14, hvor computersystemet er en håndholdt enhed.
DK10779928.0T 2009-05-27 2010-05-27 Fremgangsmåder til sygdomsbehandling DK2435825T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18150809P 2009-05-27 2009-05-27
PCT/AU2010/000649 WO2010135781A1 (en) 2009-05-27 2010-05-27 Methods of treating diseases

Publications (1)

Publication Number Publication Date
DK2435825T3 true DK2435825T3 (da) 2015-10-19

Family

ID=43222057

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10779928.0T DK2435825T3 (da) 2009-05-27 2010-05-27 Fremgangsmåder til sygdomsbehandling

Country Status (11)

Country Link
US (4) US9122778B2 (da)
EP (2) EP2435825B8 (da)
AU (1) AU2010251880B2 (da)
CA (1) CA2763373C (da)
DK (1) DK2435825T3 (da)
ES (1) ES2548508T3 (da)
HK (2) HK1167017A1 (da)
HU (1) HUE026456T2 (da)
PL (1) PL2435825T3 (da)
PT (1) PT2435825E (da)
WO (1) WO2010135781A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
ES2357430T3 (es) * 2003-10-24 2011-04-26 Immunaid Pty Ltd Método de terapia.
ES2383103T3 (es) * 2004-09-08 2012-06-18 Immunaid Pty Ltd Estrategia terapéutica para tratar enfermedades autoinmunitarias y degenerativas
CA2763373C (en) 2009-05-27 2018-01-09 Immunaid Pty Ltd Methods and systems for determining preferred times for administering therapy to treat diseases
WO2011045704A1 (en) * 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
EP2862111A4 (en) * 2012-06-18 2016-01-20 Mayo Foundation DETERMINATION OF EFFICIENT TIMES FOR THE ADMINISTRATION OF CHEMOTHERAPY
WO2014145906A2 (en) 2013-03-15 2014-09-18 Phd Preventative Health Care And Diagnostics, Inc. A prefilled medication device, method of making and using the same
EP3226750A4 (en) * 2014-12-05 2018-07-04 Lifecycle Technologies Pty Ltd Method and system for improving a physiological response
US10362998B2 (en) 2016-02-25 2019-07-30 Samsung Electronics Co., Ltd. Sensor-based detection of changes in health and ventilation threshold
US10172517B2 (en) 2016-02-25 2019-01-08 Samsung Electronics Co., Ltd Image-analysis for assessing heart failure
US11164596B2 (en) 2016-02-25 2021-11-02 Samsung Electronics Co., Ltd. Sensor assisted evaluation of health and rehabilitation
US10420514B2 (en) 2016-02-25 2019-09-24 Samsung Electronics Co., Ltd. Detection of chronotropic incompetence
EP3542859A1 (en) 2018-03-20 2019-09-25 Koninklijke Philips N.V. Determining a medical imaging schedule
CN110764975B (zh) * 2018-07-27 2021-10-22 华为技术有限公司 设备性能的预警方法、装置及监控设备
CN110083951B (zh) * 2019-04-30 2023-06-02 贵州电网有限责任公司 一种基于变压器相关运行数据的固体绝缘寿命预测方法
CN112652402B (zh) * 2020-12-11 2021-10-15 华中科技大学 一种基于磁纳米粒子谐波响应的病毒检测方法及系统

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US5308626A (en) 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5141867A (en) 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
US5057423A (en) 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
DE3812605A1 (de) 1988-04-15 1990-06-07 Leskovar Peter Dipl Ing Dr Hab Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes
US20020094542A1 (en) 1988-04-15 2002-07-18 Peter Leskovar Drugs and methods for treating cancer
AU622926B2 (en) 1988-09-09 1992-04-30 Nippon Kayaku Kabushiki Kaisha Pyrimidine or purine cyclobutane derivatives
ATE135113T1 (de) 1988-12-20 1996-03-15 Clarity Technologies Inc Synthetische hiv ähnliche peptide, deren zusammensetzungen und verwendungen
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL102092A (en) 1991-06-11 1996-11-14 Microgenesys Inc Use of recombinant VIH protein wrapped in VIH abduction drug and a pharmaceutical preparation containing the accumulated protein
DE4120296A1 (de) 1991-06-28 1992-03-19 Regina Tilgner Rein pflanzliches kombinationspraeparat - gegen aids
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
WO1994007921A1 (en) 1992-09-25 1994-04-14 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
US5358852A (en) 1992-12-21 1994-10-25 Eastman Kodak Company Use of calcium in immunoassay for measurement of C-reactive protein
JP2877673B2 (ja) 1993-09-24 1999-03-31 富士通株式会社 時系列データ周期性検出装置
WO1995020660A2 (en) 1994-01-27 1995-08-03 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
IL117574A0 (en) 1995-04-03 1996-07-23 Bristol Myers Squibb Co Processes for the preparation of cyclobutanone derivatives
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5939400A (en) 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US6077665A (en) 1996-05-07 2000-06-20 The Board Of Trustees Of The Leland Stanford Junior University Rapid assay for infection in neonates
US6110898A (en) 1996-05-24 2000-08-29 University Of Maryland, Baltimore DNA vaccines for eliciting a mucosal immune response
US20040203024A1 (en) 1996-06-06 2004-10-14 Baker Brenda F. Modified oligonucleotides for use in RNA interference
ZA975889B (en) 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6107020A (en) 1996-09-20 2000-08-22 Roger Williams Hospital Model for protective and pathogenic roles of HIV-1 env-directed antibody dependent cellular cytotoxicity interaction with viral load, and uses thereof
US7030152B1 (en) 1997-04-02 2006-04-18 The Brigham And Women's Hospital, Inc. Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
JPH11271304A (ja) 1998-03-24 1999-10-08 Jcr Pharmaceuticals Co Ltd Ｈｉｖ感染の診断方法
JP2003528564A (ja) 1998-06-06 2003-09-30 ジェノスティック ファーマ リミテッド 遺伝的プロファイリングに使用するプローブ
CA2380018A1 (en) 1999-07-28 2001-02-08 The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services Immunotherapy in hiv infected persons using vaccines after multi-drug treatment
US6980958B1 (en) 2000-01-11 2005-12-27 Zycare, Inc. Apparatus and methods for monitoring and modifying anticoagulation therapy of remotely located patients
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
US20030228320A1 (en) 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
AUPQ948800A0 (en) 2000-08-18 2000-09-07 Immunaid Pty Ltd A vaccine strategy
WO2002045735A2 (en) 2000-12-08 2002-06-13 University Technologies International, Inc. Nrp-derived peptides useful for treating insulin-dependent diabetes mellitus
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
US20060134713A1 (en) 2002-03-21 2006-06-22 Lifescan, Inc. Biosensor apparatus and methods of use
KR20050083855A (ko) 2002-11-01 2005-08-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법
US20040192629A1 (en) 2002-11-04 2004-09-30 University Of Massachusetts Allele-specific RNA interference
JP2007525416A (ja) 2003-01-31 2007-09-06 アルボア バイオロジクス， インコーポレイテッド 早期活性化分子のターゲティングに基づく免疫調節
WO2005034995A1 (en) 2003-09-10 2005-04-21 Chiron Corporation Prion chimeras and uses thereof
ES2357430T3 (es) 2003-10-24 2011-04-26 Immunaid Pty Ltd Método de terapia.
CN1953767B (zh) 2004-01-08 2011-03-16 加利福尼亚大学董事会 调节t细胞抑制自身免疫
EP1711208A2 (en) 2004-01-28 2006-10-18 Curix APS Conjugates of amyloid proteins as vaccines for amyloid-related diseases
ES2383103T3 (es) 2004-09-08 2012-06-18 Immunaid Pty Ltd Estrategia terapéutica para tratar enfermedades autoinmunitarias y degenerativas
CA2582739A1 (en) 2004-09-30 2006-04-13 Bayer Healthcare Ag Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
FR2877227B1 (fr) 2004-11-03 2008-01-04 Braun Medical Soc Par Actions Systeme medical d'injection a optimisation de therapie
WO2006072011A2 (en) 2004-12-30 2006-07-06 Proventys, Inc. Methods, systems, and computer program products for developing and using predictive models for predicting a plurality of medical outcomes, for evaluating intervention strategies, and for simultaneously validating biomarker causality
JP4806674B2 (ja) 2005-03-07 2011-11-02 学校法人順天堂 持続皮下インスリン注入療法
US20090061422A1 (en) 2005-04-19 2009-03-05 Linke Steven P Diagnostic markers of breast cancer treatment and progression and methods of use thereof
US20070172844A1 (en) 2005-09-28 2007-07-26 University Of South Florida Individualized cancer treatments
GB2436616A (en) 2006-03-29 2007-10-03 Inverness Medical Switzerland Assay device and method
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
US20090105167A1 (en) 2007-10-19 2009-04-23 Duke University Predicting responsiveness to cancer therapeutics
EP2307050A4 (en) 2008-07-04 2012-07-25 Ono Pharmaceutical Co USE OF A EFFECTIVENESS MARKER TO OPTIMIZE THE THERAPEUTIC EFFECTIVENESS OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS
CA2763373C (en) 2009-05-27 2018-01-09 Immunaid Pty Ltd Methods and systems for determining preferred times for administering therapy to treat diseases
AU2010332283B2 (en) 2009-12-17 2014-06-12 Mayo Foundation For Medical Education And Research Determination of favorable time(s) for chemotherapy delivery
EP2862111A4 (en) 2012-06-18 2016-01-20 Mayo Foundation DETERMINATION OF EFFICIENT TIMES FOR THE ADMINISTRATION OF CHEMOTHERAPY

Also Published As

Publication number Publication date
US20130218475A1 (en) 2013-08-22
US9239904B2 (en) 2016-01-19
EP2435825B8 (en) 2015-09-02
EP2435825A4 (en) 2012-11-28
ES2548508T3 (es) 2015-10-19
HK1217763A1 (zh) 2017-01-20
US9268908B2 (en) 2016-02-23
EP2435825B1 (en) 2015-07-15
HUE026456T2 (en) 2016-05-30
WO2010135781A1 (en) 2010-12-02
PL2435825T3 (pl) 2015-12-31
AU2010251880B2 (en) 2015-07-30
US10714208B2 (en) 2020-07-14
US20120220640A1 (en) 2012-08-30
AU2010251880A1 (en) 2011-12-22
EP2982978A1 (en) 2016-02-10
CA2763373A1 (en) 2010-12-02
US20130151165A1 (en) 2013-06-13
US20160125125A1 (en) 2016-05-05
HK1167017A1 (en) 2012-11-16
EP2435825A1 (en) 2012-04-04
PT2435825E (pt) 2015-11-02
US9122778B2 (en) 2015-09-01
CA2763373C (en) 2018-01-09

Similar Documents

Publication Publication Date Title
US10714208B2 (en) Computer systems for treating diseases
CN103097888B (zh) 利用克隆型谱监测健康和疾病状态
Valent et al. Multidisciplinary challenges in mastocytosis and how to address with personalized medicine approaches
US20150110805A1 (en) Therapeutic strategy for treating autoimmune and degenerative diseases
CN104769168A (zh) 发现治疗靶标的方法
BR112020010430A2 (pt) biomarcadores e métodos inovadores para diagnosticar e avaliar lesão cerebral traumática
CN110268383A (zh) 综合、分子、组学、免疫疗法、代谢、表观遗传学和临床数据库
Pham et al. Preclinical models of pancreatic ductal adenocarcinoma and their utility in immunotherapy studies
Wang et al. Emerging roles of ALK in immunity and insights for immunotherapy
Forconi et al. Biological and clinical insight from analysis of the tumor b-cell receptor structure and function in chronic lymphocytic leukemia
Bose Preferentially Expressed Antigen in Melanoma Is a Multifaceted Cancer Testis Antigen with Diverse Roles as a Biomarker and Therapeutic Target
WO2019177152A1 (ja) 免疫実体の効率的クラスタリング
Jõgi et al. New onset generalized myasthenia gravis evolving following SARS-CoV-2 infection
Sergeant et al. OP0013 prediction of non-response to methotrexate therapy in the Rheumatoid Arthritis Medication Study (RAMS)
Bretscher What Determines the Class of Immunity an Antigen Induces? A Foundational Question Whose Rational Consideration Has Been Undermined by the Information Overload
AU2005282218B2 (en) Therapeutic strategy for treating autoimmune and degenerative diseases
Nielsen et al. Delayed booster dosing improves human antigen-specific Ig and B cell responses to the RH5. 1/AS01B malaria vaccine
Wu The cerebrospinal fluid immune cell landscape in animal models of multiple sclerosis
Dziadkowiak et al. Molecular, Electrophysiological, and Ultrasonographic Differences in Selected Immune-Mediated Neuropathies with Therapeutic Implications
EP4330969A1 (en) Machine learning techniques for estimating tumor cell expression in complex tumor tissue
de Carvalho et al. Lack of anti-insulin, anti-GAD, and anti-IA2 autoantibodies in primary antiphospholipid syndrome
Mok et al. www. currentmedicalliterature. com
JP2018525002A (ja) 疾患および障害の個別化された治療